News ArchivesRead News
Faulty enzyme sparks Parkinson’s disease
Thursday June 23, 2005
June 22, 2005(ScienceDaily) - Parkinson’s disease is caused by a faulty enzyme that causes brain proteins to clump -- much like Alzheimer’s or Huntington’s disease, Texas researchers say.
Parkinson’s is "a disease involving accumulation of a protein in an aberrant form," said Philip Thomas, lead researcher at the University of Texas’ Southwestern Medical Center.
Normally, the protein involved in Parkinson’s, alpha-synuclein, unfolds when it is stressed and is chewed into harmless bits by an enzyme.
However, that enzyme malfunctions in Parkinson’s patients and creates protein fragments that clump, and those protein clusters cause more clumps in "vicious cycle" of the degenerative disease, scientists said.
Thomas, reporting in The Journal of Biological Chemistry, said future research may involve ways to inhibit the malicious form of the enzyme while leaving the normal form alone since the enzyme is essential for cells to survive.
Recent NewsOct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show